Antibody Therapeutics

Published in 1997: Antibody Therapeutics is a comprehensive evaluation of progress toward using humanized antibodies as a new generation of therapeutics. The humanized antibodies that have led the way in product approval are discussed as case studies, offering an insight into the preclinical and clinical data acquired during the regulatory approval process. Leading experts offer their findings as examples of what works and what does not, saving you time and making your research more cost effective. This book is essential reading for researchers, clinicians, development and regulatory staff in pharmaceutical and biotechnology companies, and hospital staff, including policy and decision makers. It also provides postgraduate and medical students with an authoritative overview of the field.

Part 1: Antibodies as Therapeutics 1. Unconjugated Antibodies as Therapeutics M. Clark 2. Immunotoxins for Treating Cancer and Autoimmune Disease R.J. Kreitman and I. Pastan 3. Antibodies as Carriers for Drug and Radioisotopes G. Yarranton 4. Tumor Targeting by Antibody-Drug Conjugates I. Benhar and I. Pastan Part 2: Application of Antibody Therapeutics 5. Therapeutic Antibodies in Infectious Disease W.J. Harris 6. Antibody Therapeutics: Application to Autoimmunity L. Chatenoud 7. Monoclonal Antibodies in Transplantation M.-L. Alegre Part 3: Development of Antibody Therapeutics 8. Regulatory Issues for the Development of Antibody Therapeutics K.J. Lambert 9. Manufacture of Antibodies by Large Scale Mammalian Cell Culture D.K. Robinson, V. Yabannavar, and Y. Deo 10. Production of Antibody Domains in Prokaryotes M. Better and P. Gavit 11. Emerging Production Systems for Antibody Therapeutics A.J.R. Porter et al. Part 4: Recombinant Antibodies in the Clinic 12. Development of Zenapax™: A Humanized Anti-Tac Antibody J. Hakimi et al. 13. Progress with a Reshaped Monoclonal Antibody, RSHZ19, for the Prophylaxis and Treatment of Respiratory Syncytial Virus Infection S.B. Dillon and T.G. Porter 14. CDP571, An Engineered Antibody to Human Tumor Necrosis Factor S. Stevens, O. Vetterlein, and M. Sopwith 15. The Therapeutic Potential of a Primatized, Nondepleting Anti-CD4 (IDEC-CE9.1) Monoclonal Antibody in Rheumatoid Arthritis A.M. Solinger et al.

William J. Harris, Ph.D., C.Biol, is Professor of Genetics at the University of Aberdeen, Scotland. John R. Adair, Ph.D., is Product Development Manager at Axis Genetics, Plc.